Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
Copyright © 2023 Massachusetts Medical Society..
BACKGROUND: Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
METHODS: In this multinational, phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients with primary biliary cholangitis who had had an inadequate response to or unacceptable side effects with ursodeoxycholic acid to receive once-daily elafibranor, at a dose of 80 mg, or placebo. The primary end point was a biochemical response (defined as an alkaline phosphatase level of <1.67 times the upper limit of the normal range, with a reduction of ≥15% from baseline, and normal total bilirubin levels) at week 52. Key secondary end points were normalization of the alkaline phosphatase level at week 52 and a change in pruritus intensity from baseline through week 52 and through week 24, as measured on the Worst Itch Numeric Rating Scale (WI-NRS; scores range from 0 [no itch] to 10 [worst itch imaginable]).
RESULTS: A total of 161 patients underwent randomization. A biochemical response (the primary end point) was observed in 51% of the patients (55 of 108) who received elafibranor and in 4% (2 of 53) who received placebo, for a difference of 47 percentage points (95% confidence interval [CI], 32 to 57; P<0.001). The alkaline phosphatase level normalized in 15% of the patients in the elafibranor group and in none of the patients in the placebo group at week 52 (difference, 15 percentage points; 95% CI, 6 to 23; P = 0.002). Among patients who had moderate-to-severe pruritus (44 patients in the elafibranor group and 22 in the placebo group), the least-squares mean change from baseline through week 52 on the WI-NRS did not differ significantly between the groups (-1.93 vs. -1.15; difference, -0.78; 95% CI, -1.99 to 0.42; P = 0.20). Adverse events that occurred more frequently with elafibranor than with placebo included abdominal pain, diarrhea, nausea, and vomiting.
CONCLUSIONS: Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo. (Funded by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, NCT04526665.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 390(2024), 9 vom: 29. Feb., Seite 795-805 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kowdley, Kris V [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 01.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT04526665 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2306185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364537140 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364537140 | ||
| 003 | DE-627 | ||
| 005 | 20240301232128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2306185 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM364537140 | ||
| 035 | |a (NLM)37962077 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kowdley, Kris V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04526665 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Primary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown | ||
| 520 | |a METHODS: In this multinational, phase 3, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients with primary biliary cholangitis who had had an inadequate response to or unacceptable side effects with ursodeoxycholic acid to receive once-daily elafibranor, at a dose of 80 mg, or placebo. The primary end point was a biochemical response (defined as an alkaline phosphatase level of <1.67 times the upper limit of the normal range, with a reduction of ≥15% from baseline, and normal total bilirubin levels) at week 52. Key secondary end points were normalization of the alkaline phosphatase level at week 52 and a change in pruritus intensity from baseline through week 52 and through week 24, as measured on the Worst Itch Numeric Rating Scale (WI-NRS; scores range from 0 [no itch] to 10 [worst itch imaginable]) | ||
| 520 | |a RESULTS: A total of 161 patients underwent randomization. A biochemical response (the primary end point) was observed in 51% of the patients (55 of 108) who received elafibranor and in 4% (2 of 53) who received placebo, for a difference of 47 percentage points (95% confidence interval [CI], 32 to 57; P<0.001). The alkaline phosphatase level normalized in 15% of the patients in the elafibranor group and in none of the patients in the placebo group at week 52 (difference, 15 percentage points; 95% CI, 6 to 23; P = 0.002). Among patients who had moderate-to-severe pruritus (44 patients in the elafibranor group and 22 in the placebo group), the least-squares mean change from baseline through week 52 on the WI-NRS did not differ significantly between the groups (-1.93 vs. -1.15; difference, -0.78; 95% CI, -1.99 to 0.42; P = 0.20). Adverse events that occurred more frequently with elafibranor than with placebo included abdominal pain, diarrhea, nausea, and vomiting | ||
| 520 | |a CONCLUSIONS: Treatment with elafibranor resulted in significantly greater improvements in relevant biochemical indicators of cholestasis than placebo. (Funded by GENFIT and Ipsen; ELATIVE ClinicalTrials.gov number, NCT04526665.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid |2 NLM | |
| 650 | 7 | |a Alkaline Phosphatase |2 NLM | |
| 650 | 7 | |a EC 3.1.3.1 |2 NLM | |
| 650 | 7 | |a Bilirubin |2 NLM | |
| 650 | 7 | |a RFM9X3LJ49 |2 NLM | |
| 650 | 7 | |a Chalcones |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Peroxisome Proliferator-Activated Receptors |2 NLM | |
| 650 | 7 | |a PPAR alpha |2 NLM | |
| 650 | 7 | |a PPAR delta |2 NLM | |
| 650 | 7 | |a Propionates |2 NLM | |
| 650 | 7 | |a Ursodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 724L30Y2QR |2 NLM | |
| 650 | 7 | |a Cholagogues and Choleretics |2 NLM | |
| 700 | 1 | |a Bowlus, Christopher L |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Akarca, Ulus S |e verfasserin |4 aut | |
| 700 | 1 | |a Alvares-da-Silva, Mario Reis |e verfasserin |4 aut | |
| 700 | 1 | |a Andreone, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Arrese, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Corpechot, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Francque, Sven M |e verfasserin |4 aut | |
| 700 | 1 | |a Heneghan, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Invernizzi, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kruger, Frederik C |e verfasserin |4 aut | |
| 700 | 1 | |a Lawitz, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Mayo, Marlyn J |e verfasserin |4 aut | |
| 700 | 1 | |a Shiffman, Mitchell L |e verfasserin |4 aut | |
| 700 | 1 | |a Swain, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Valera, José Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Vierling, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Villamil, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Addy, Carol |e verfasserin |4 aut | |
| 700 | 1 | |a Dietrich, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Germain, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Mazain, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Rafailovic, Dragutin |e verfasserin |4 aut | |
| 700 | 1 | |a Taddé, Bachirou |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Jianfen |e verfasserin |4 aut | |
| 700 | 1 | |a Zein, Claudia O |e verfasserin |4 aut | |
| 700 | 1 | |a Schattenberg, Jörn M |e verfasserin |4 aut | |
| 700 | 0 | |a ELATIVE Study Investigators’ Group |e verfasserin |4 aut | |
| 700 | 0 | |a ELATIVE Study Investigators' Group |e verfasserin |4 aut | |
| 700 | 1 | |a Adrover, Raúl |e investigator |4 oth | |
| 700 | 1 | |a Bessone, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Colombato, Luis |e investigator |4 oth | |
| 700 | 1 | |a Gadano, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Galdame, Omar |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Christophe |e investigator |4 oth | |
| 700 | 1 | |a Verhelst, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Cançado, Eduardo Luiz Rachid |e investigator |4 oth | |
| 700 | 1 | |a Faisal, Nabiha |e investigator |4 oth | |
| 700 | 1 | |a Vincent, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Mezzano, Gabriel |e investigator |4 oth | |
| 700 | 1 | |a Poniachik, Jaime |e investigator |4 oth | |
| 700 | 1 | |a Ratziu, Vlad |e investigator |4 oth | |
| 700 | 1 | |a Heurgué, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Hilleret, Marie-Noëlle |e investigator |4 oth | |
| 700 | 1 | |a Sogni, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Bantel, Heike |e investigator |4 oth | |
| 700 | 1 | |a Hinrichsen, Holger |e investigator |4 oth | |
| 700 | 1 | |a Hofmann, Wolf-Peter |e investigator |4 oth | |
| 700 | 1 | |a Müller, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Schiefke, Ingolf |e investigator |4 oth | |
| 700 | 1 | |a Sprinzl, Kathrin |e investigator |4 oth | |
| 700 | 1 | |a Calvaruso, Vincenza |e investigator |4 oth | |
| 700 | 1 | |a Muratori, Luigi |e investigator |4 oth | |
| 700 | 1 | |a Rajabally, Naayil |e investigator |4 oth | |
| 700 | 1 | |a Sonderup, Mark |e investigator |4 oth | |
| 700 | 1 | |a Ampuero, Javier |e investigator |4 oth | |
| 700 | 1 | |a Calleja Panero, José Luis |e investigator |4 oth | |
| 700 | 1 | |a Díaz-González, Álvaro |e investigator |4 oth | |
| 700 | 1 | |a Londoño Hurtado, María Carlota |e investigator |4 oth | |
| 700 | 1 | |a Olveira Martín, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Salcedo Plaza, Magdalena |e investigator |4 oth | |
| 700 | 1 | |a Turnes, Juan |e investigator |4 oth | |
| 700 | 1 | |a Gomes Rodrigues, Susana |e investigator |4 oth | |
| 700 | 1 | |a Terziroli Beretta-Piccoli, Benedetta |e investigator |4 oth | |
| 700 | 1 | |a Balaban, Yasemin |e investigator |4 oth | |
| 700 | 1 | |a Yilmaz, Yusuf |e investigator |4 oth | |
| 700 | 1 | |a Mells, George |e investigator |4 oth | |
| 700 | 1 | |a Cheent, Kuldeep |e investigator |4 oth | |
| 700 | 1 | |a Corless, Lynsey |e investigator |4 oth | |
| 700 | 1 | |a McCorry, Roger |e investigator |4 oth | |
| 700 | 1 | |a Sheridan, David |e investigator |4 oth | |
| 700 | 1 | |a Corregidor, Ana Maria |e investigator |4 oth | |
| 700 | 1 | |a Ankoma-Sey, Victor |e investigator |4 oth | |
| 700 | 1 | |a Ayoub, Walid S |e investigator |4 oth | |
| 700 | 1 | |a Caldwell, Stephen H |e investigator |4 oth | |
| 700 | 1 | |a Elbeshbeshy, Hany |e investigator |4 oth | |
| 700 | 1 | |a Forman, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Galambos, Michael |e investigator |4 oth | |
| 700 | 1 | |a Ghalib, Reem |e investigator |4 oth | |
| 700 | 1 | |a Gilroy, Richard K |e investigator |4 oth | |
| 700 | 1 | |a Gordon, Stuart C |e investigator |4 oth | |
| 700 | 1 | |a Jacobson, Ira M |e investigator |4 oth | |
| 700 | 1 | |a Khemichian, Saro |e investigator |4 oth | |
| 700 | 1 | |a Krok, Karen L |e investigator |4 oth | |
| 700 | 1 | |a Kugelmas, Marcelo |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Sonal |e investigator |4 oth | |
| 700 | 1 | |a Mehta, Ashwini P |e investigator |4 oth | |
| 700 | 1 | |a Mubarak, Abdullah |e investigator |4 oth | |
| 700 | 1 | |a Muir, Andrew J |e investigator |4 oth | |
| 700 | 1 | |a Post, Anthony |e investigator |4 oth | |
| 700 | 1 | |a Pratt, Daniel S |e investigator |4 oth | |
| 700 | 1 | |a Rabinovitz, Mordechai |e investigator |4 oth | |
| 700 | 1 | |a Ravinuthala, Ravi |e investigator |4 oth | |
| 700 | 1 | |a Rockey, Don C |e investigator |4 oth | |
| 700 | 1 | |a Ruane, Peter J |e investigator |4 oth | |
| 700 | 1 | |a Russo, Mark W |e investigator |4 oth | |
| 700 | 1 | |a Sass, David A |e investigator |4 oth | |
| 700 | 1 | |a Scanga, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Silveira, Marina G |e investigator |4 oth | |
| 700 | 1 | |a Verma, Dharmendra |e investigator |4 oth | |
| 700 | 1 | |a Yimam, Kidist K |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 390(2024), 9 vom: 29. Feb., Seite 795-805 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2024 |g number:9 |g day:29 |g month:02 |g pages:795-805 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2306185 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2024 |e 9 |b 29 |c 02 |h 795-805 | ||